Ampersand buys AccuMed after merger talks fail:
This article was originally published in Clinica
AccuMed has signed a definitive agreement to be acquired by Ampersand Medical in a share deal, three months after Ampersand terminated merger negotiations between the two companies. At that time, the companies agreed to discuss further possibilities (see Clinica No 938, p 12). Ampersand is a cancer diagnostic company and uses AccuMed's AcCell automated microscopy technology in clinical trials of its InPath cervical cancer detection system. Both companies are based in Chicago.